Scarica l'app Stockscreener
4.71
0.64%
0.03
Precedente Chiudi:
$4.68
Aprire:
$4.69
Volume 24 ore:
85,254
Relative Volume:
0.53
Capitalizzazione di mercato:
$126.03M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-15.29%
1M Prestazione:
-41.64%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.52
$4.82
Intervallo di 1 settimana:
$4.52
$5.7899
Portata 52W:
$4.52
$18.79
Conexeu Sciences Inc Stock (CNXU) Company Profile
Nome
Conexeu Sciences Inc
Settore
Industria
Telefono
604-315-4722
Indirizzo
50 WEST LIBERTY STREET, SUITE 880, RENO
Compare CNXU vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNXU
Conexeu Sciences Inc
|
4.71 | 125.23M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
520.76 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.41 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.47 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.29 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.94 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Conexeu Sciences Inc Borsa (CNXU) Ultime notizie
Top Conexeu Sciences (CNXU) Competitors 2026 - MarketBeat
CNXU Should I Buy - Intellectia AI
Ambarella Q2 Revenue Rises 12% as Net Loss Narrows Sharply - minichart.com.sg
Investment fund caps Conexeu Sciences (CNXU) stake below 10% - Stock Titan
Near-10% stake in Conexeu (CNXU) tied to warrant cap - Stock Titan
Conexeu Sciences (NASDAQ:CNXU) Shares Down 5.2%Here's What Happened - MarketBeat
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture - Finansavisen
Conexeu Steps Up Investor Outreach Ahead of Key Regulatory Milestones - TipRanks
Conexeu Sciences Sets September and October 2026 Conference Schedule - The Manila Times
At Nasdaq headquarters, a biotech company will present Sept. 9, then attend two more events. - Stock Titan
Conexeu Sciences (CNXU) pays consultants with $88K in stock - Stock Titan
Here's Why We're Not Too Worried About Conexeu Sciences' (NASDAQ:CNXU) Cash Burn Situation - webull.com
Conexeu Sciences (CNXU) Insider Trading Activity 2026 - MarketBeat
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - Eastern Progress
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It. - The Spec
The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too. - marketscreener.com
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration - Moomoo
Jeffrey Sharpe Discloses Investment at Conexeu Sciences Inc. with 5.4% Stake - TradingView
2.3M-share stake in Conexeu Sciences (CNXU) revealed by single investor - Stock Titan
Conexeu (CNXU) director gets $0.001 warrants tied to Nasdaq, FDA goals - Stock Titan
CNXU - Finviz
Conexeu Sciences Inc. (CNXU) BetaZacks.com - Zacks Investment Research
CNXU : Conexeu Sciences Inc. Key Company Details - Zacks Investment Research
Conexeu Sciences (CNXU) Stock Trends and Sentiment 2026 - MarketBeat
Conexeu Sciences (CNXU) investor reports 12.3% stake and warrant-linked shares - Stock Titan
Conexeu Sciences Inc. (CNXU) investor discloses 5.5% stake in Schedule 13G filing - Stock Titan
OnePointTwo Capital Ventures (CNXU) discloses 1.88M-share Conexeu Sciences stake - Stock Titan
One Platform, Five Markets: Insights Into Conexeu Sciences Inc. - SmallCap Asia
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For - marketscreener.com
Conexeu to Present at 2026 Controversies & Conversations in Laser and Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration - marketscreener.com
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It - marketscreener.com
Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium - TipRanks
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration - The Manila Times
Beyond volume: Conexeu to discuss the body's repair process - Stock Titan
Conexeu Sciences Ord Shs (CNXU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma’s TriKE® Program: Pipeline, Progress, & What’s Ahead - SmallCap Asia
Price to earnings forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One - Investing News Network
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison - IPO Edge
Conexeu Sciences (CNXU) investor Michael G. Wright discloses 12.1% ownership stake - Stock Titan
Short Interest in Conexeu Sciences Inc. (NASDAQ:CNXU) Expands By 357.1% - MarketBeat
CNXU|Conexeu Sciences Ord Shs|Price:8.630|Chg%:-1.360 - TradingKey
Conexeu Sciences Inc. Revenue Breakdown – NASDAQ:CNXU - TradingView
Paisley Capital reports 1.8M-share position in Conexeu Sciences Inc. (CNXU) - Stock Titan
David Robert Bogart Net Worth (2026) - GuruFocus
Ana Lucia Bastiani Posner Net Worth (2026) - GuruFocus
Aaron Solomon Farberg Net Worth (2026) - GuruFocus
Jeffrey Nathan Sharpe Net Worth (2026) - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Conexeu Sciences Inc.Common Stock (CNXU) Stock Price, News, Quote & History - FinancialContent
Breakeven Is Near for Pulsar Group plc (LON:PULS) - simplywall.st
Conexeu Sciences Inc Azioni (CNXU) Dati Finanziari
Non sono disponibili dati finanziari per Conexeu Sciences Inc (CNXU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
2.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):